Description:
Semaxanib is a quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
- Molecular Weight:238.28
- Melting Point:>190ºC (dec.)
- Purity:98%
Molecular Formula:
C15H14N2O
Canonical SMILES:
CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
InChI:
InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
InChIKey:
WUWDLXZGHZSWQZ-WQLSENKSSA-N
Appearance:
Yellow to Orange Solid Powder
Application:
Angiogenesis Inhibitors
Synonyms:
SU5416; SU-5416; SU 5416; Sugen 5416; semoxind Weitere Informationen finden Sie
hier